Contact Us
Drug Search Results
More Filters [+]

Altiratinib

Alternative Names: altiratinib, dcc-2701, dcc-270
Latest Update: 2024-03-01
Latest Update Note: PubMed Publication

Product Description

Altiratinib is an orally bioavailable inhibitor of c-Met/hepatocyte growth factor receptor (HGFR), vascular endothelial growth factor receptor type 2 (VEGFR2), Tie2 receptor tyrosine kinase (TIE2), and tropomyosin receptor kinase (Trk), with potential antiangiogenic and antineoplastic activities.  (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Altiratinib)

Mechanisms of Action: C-Met Inhibitor,VEGFR2 Inhibitor,ANG Inhibitor,TRK Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Deciphera
Company Location: WALTHAM MA 02451
Company CEO: Steven L. Hoerter
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Altiratinib

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
DCC-2701-01-001

P1

Terminated

Oncology Solid Tumor Unspecified

2017-11-01

Recent News Events

Date

Type

Title

03/01/2024

PubMed

 Engineering small-molecule analogues of altiratinib via CREB-regulated transcription co-activator 3-target screening for the development of potent and safe topical therapeutics against skin hyperpigmentary diseases.

08/03/2022

PubMed

 Altiratinib blocks Toxoplasma gondii and Plasmodium falciparum development by selectively targeting a spliceosome kinase.

06/11/2022

PubMed

 Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions